Put companies on watchlist
SynBiotic SE
ISIN: DE000A3E5A59
WKN: A3E5A5
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

SynBiotic SE · ISIN: DE000A3E5A59 · EQS - Company News (19 News)
Country: Germany · Primary market: Germany · EQS NID: 1239995
12 October 2021 10:00AM

SynBiotic SE plans Canadian cross-listing



DGAP-Media / 12.10.2021 / 10:00

SynBiotic SE plans Canadian cross-listing

Munich, October 12, 2021. The cannabis company SynBiotic SE (ISIN: DE000A2LQ777 / WKN: A2LQ77), already listed on the Frankfurt and Düsseldorf stock exchanges, is now to be listed on the Canadian NEO Exchange in Toronto - a new FinTech stock exchange that has been revolutionizing the market since 2014, offering modern services across the capital market. The Board of Directors and the Managing Director have announced passing a corresponding resolution.

Lars Müller, CEO of SynBiotic SE, explains: "Canada is the flagship country when it comes to the cannabis industry. The sector there is particularly well developed, with a number of listed companies and billions in market capitalization. Above all, having our own Canadian listing makes it easier for us to gain access to specialized investors. In the Canadian capital market, we also ensure ourselves of a completely different degree of attention to and understanding of our issue - and can thus better exploit the opportunities to access capital."

All of this would be facilitated by the platform company being in the midst of its peer group on the new NEO Exchange. With the Canadian top dogs Tilray, Canopy Growth or the Cronos Group, a vastly improved comparability to that enjoyed in Europe would follow. Müller continues: "Analysts, market observers and investors will look at us with different eyes - but so will the Canadian competition. Because at the latest, when they further expand into Europe, they will be on the lookout for cooperation partners. Therefore, our envisaged move to go public on the NEO Exchange is also a strategic step."

About SynBiotic SE
SynBiotic SE is the first German listed cannabis company to pursue an EU-focused buy-and-build investment approach. The core business of the platform company is the research and development of new cannabinoid and terpene-based solutions to major social problems such as pain, sleep-disorders and anxiety. In addition, the platform deals with the production of various cannabinoids and develops and distributes pharmaceutical and dietary supplements as well as cosmetic products under its own brands.



End of Media Release


Issuer: SynBiotic SE
Key word(s): Finance

12.10.2021 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: SynBiotic SE
Barer Str. 7
80333 München
Germany
E-mail: office@synbiotic.com
Internet: https://www.synbiotic.com/
ISIN: DE000A3E5A59
WKN: A3E5A5
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Tradegate Exchange
EQS News ID: 1239995

 
End of News DGAP Media

1239995  12.10.2021 

fncls.ssp?fn=show_t_gif&application_id=1239995&application_name=news&site_id=boersengefluester_html
Visual performance / price development - SynBiotic SE
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.